Elsevier

Elsevier is a publishing company from the Netherlands that focuses on scientific, technical, and medical information. It is a division of the RELX Group, which was previously known as Reed Elsevier until 2015. Among its offerings are well-known journals like The Lancet and Cell, along with the ScienceDirect platform that provides access to a wide range of electronic journals. They also publish the Trends and Current Opinion journal series, and manage the Scopus citation database. Additionally, Elsevier offers the SciVal tool for evaluating research impact, the ClinicalKey search engine designed for healthcare professionals, and the ClinicalPath service that supports evidence-based cancer treatment. Their portfolio also includes various digital tools aimed at data management, teaching, research analysis, and performance assessment.

International

English

Media Company

Outlet metrics

Domain Authority

Ranking

Global

#1198

United States

#950

Science and Education/Social Sciences

Traffic sources

Monthly visitors

Articles

Flipping a flagship journal to open access

1 month ago | elsevier.com | Libby Plummer

Flipping a flagship journal to open access might seem daunting, especially at the same time as changing publishers, but the International Association for Food Protection’s successful switch proves that it might not be as hard as you think. The International Association for Food Protection opens in new tab/window (IAFP) moved its flagship publication, the Journal of Food Protection opens in new tab/window, to an open access model in 2023, which coincided with its move to Elsevier.
More early career researchers are stepping up to peer review

Jan 15, 2025 | elsevier.com | Liana Cafolla

Younger researchers are discovering new opportunities as they take on the challenges of peer reviewAs with many early career researchers, a typical day for Dr Wilson Poon opens in new tab/window features a packed agenda. Now in his third year as Assistant Professor of Biomedical Engineering at the University of Texas at El Paso, he combines biomedical engineering and pure biology research in his lab as well as working with 12 students.
AI and health equity in cancer: 3 areas of progress

Dec 12, 2024 | elsevier.com | Alison Bert

Prof Jakob Kather’s research team at Else Kröner Fresenius Center for Digital Health at TUD Dresden University of Technology in Germany is using AI to revolutionize oncology treatment through biomarker extraction. Dr Karin Dembrower, Senior Breast Radiologist at St Göran’s Hospital in Sweden, is overseeing a program using AI technology for breast cancer screening with promising results.
New editor perspectives: Dirk Van Raemdonck

Nov 28, 2024 | elsevier.com | Dirk Van Raemdonck

“The role of editor is one which requires a close awareness of the development of the field”In this series for Editors' Update we talk to recently appointed editors to learn about their experiences of editing thus far. We aim to find out how they came into the role, what (if anything) has surprised them about the work, what tools they find useful, and what advice they would give to a colleague contemplating a similar position.
How ‘privacy by design’ protects your personal data

Nov 21, 2024 | elsevier.com | Simon Wright

By building privacy into the product design process, we can help ensure users’ personal data is secureAs our lives increasingly move online, we have reason to question how our personal data is being used and whether it’s being protected. What data has an organization collected about us? How long it is being stored, and how it is being managed? And most importantly, is it secure? This is where “privacy by design” comes in.
Chemists unite! InChI is now built for collaboration — and scale

Nov 21, 2024 | elsevier.com | Ann-Marie Roche

The InChI story is something like a Hollywood movie. It’s about the quest to encode the essential structural information of a chemical into a character string so it can be used, shared and found by any interested party. It features an unsung cast of quirky characters. And now, there’s even a happy ending that offers a new beginning for any organization seeking to pursue its chemical interests without sacrificing IP.
revisiting the role of university leaders

Nov 17, 2024 | elsevier.com | Peter Salovey

How do we promote free expression in an era that values social harmony? Can university presidents lead if “neutrality” is the institutional voice? We have seen more than the usual number of events on campuses across this country in which the freedom to express ideas has been threatened. Invitations to provocative speakers have been withdrawn. Politicians, celebrities and even university presidents invited to deliver commencement addresses have — under pressure — declined to speak to graduates.
New editor perspectives: Young Jik Kwon

Nov 4, 2024 | elsevier.com | Young Jik Kwon

“What is seen “from the outside” is a quite small fraction of the job”In this series for Editors' Update we talk to recently appointed editors to learn about their experiences of editing thus far. We aim to find out how they came into the role, what (if anything) has surprised them about the work, what tools they find useful, and what advice they would give to a colleague contemplating a similar position.
How life sciences researchers regard and use AI

Oct 23, 2024 | elsevier.com | Ann-Marie Roche

We can safely use an overused word like “gamechanger” for ChatGPT. When released in November 2022, it triggered a revolutionary shift across many sectors, including R&D. However, two years later, while generative AI continues to evolve rapidly, we are still largely figuring out what these changes entail.
Interested in publishing open access? We can help!

Oct 16, 2024 | elsevier.com | Linda Willems

We take a look at how Elsevier’s open access initiatives are supporting authors globallyFor a number of years now, we’ve been working closely with the research community to develop a range of flexible, inclusive and accessible open access (OA) options for authors. In this article, we take a look at three key focus areas.